A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma.

Trial Profile

A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PANORAMA 2; PANORAMA-II
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2014 According to a Novartis media release, the FDA Oncologic Drugs Advisory Committee did not recommend panobinostat for previously treated multiple myeloma.
    • 04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Dec 2013 Interim time to event analyses presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top